Recent Analysts’ Ratings Changes for BridgeBio Oncology Therapeutics (BBOT)

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) has recently received a number of price target changes and ratings updates:

• 10/21/2026 – BridgeBio Oncology Therapeutics had its price target lowered by Morgan Stanley to $13.00. They now have an “overweight” rating on the stock.
• 10/20/2026 – BridgeBio Oncology Therapeutics had its price target lowered by Oppenheimer to $16.00. They now have an “outperform” rating on the stock.
• 10/17/2026 – BridgeBio Oncology Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 10/9/2026 – BridgeBio Oncology Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/14/2026 – BridgeBio Oncology Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/12/2026 – BridgeBio Oncology Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 9/11/2026 – BridgeBio Oncology Therapeutics had its price target lowered by JPMorgan Chase & Co. from $25.00 to $23.00. They now have an “overweight” rating on the stock.
• 9/10/2026 – BridgeBio Oncology Therapeutics had its price target lowered by Leerink Partners to $27.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – BridgeBio Oncology Therapeutics had its price target lowered by Raymond James Financial from $24.00 to $22.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – BridgeBio Oncology Therapeutics had its price target lowered by Stifel Nicolaus from $23.00 to $15.00. They now have a “buy” rating on the stock.
• 9/9/2026 – BridgeBio Oncology Therapeutics had its price target lowered by Canaccord Genuity Group from $23.00 to $20.00. They now have a “buy” rating on the stock.
• 9/9/2026 – BridgeBio Oncology Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $25.00 price target on the stock.

BridgeBio Oncology Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with genetically driven cancers. The company is part of the broader BridgeBio platform, which supports the development of therapies for diseases linked to well-defined biological targets.

Its oncology programs are centered on small-molecule therapies intended to address cancer-causing genetic alterations, including targets that have historically been difficult to treat.